Drugs / Vamotinib
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02885766 | Jul 2016 → Jun 2018 | chronic myeloid leukemia | Fusion Pharma LLC | Unknown | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vamotinib | “Vamotinib (PF-114) is a 3rd -generation, ATP-competitive oral tyrosine kinase inhibitor (TKI) active against wild-type and mutated BCR::ABL1 isoforms including BCR::ABL1T315I.” PMID 40298994 ↗ Apr 2025 |
| Known as | PF-114 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02885766 ↗ |
| Action | Inhibit | “PF-114 inhibited BCR/ABL and clinically important mutants including T315I at nanomolar concentrations.” PMID 25394714 ↗ Nov 2014 |
| Modality | Small molecule | “PF-114 is a low molecular inhibitor of a Bcr-Abl kinase activity” NCT02885766 ↗ |
| Route | Oral | “Orally, once daily” NCT02885766 ↗ |
| Target | ABL1 | “Vamotinib (PF-114) is a 3rd -generation, ATP-competitive oral tyrosine kinase inhibitor (TKI) active against wild-type and mutated BCR::ABL1 isoforms including BCR::ABL1T315I.” PMID 40298994 ↗ Apr 2025 |
| Target | BCR | “PF-114 inhibited BCR/ABL and clinically important mutants including T315I at nanomolar concentrations.” PMID 25394714 ↗ Nov 2014 |